Companion Diagnostics Explained

Modern medicine increasingly recognizes that patients with the same disease may respond differently to the same treatment. Their tumors or cells may carry different mutations, express different proteins, or depend on different biological pathways. Companion diagnostics help identify these differences. A companion diagnostic test is linked to a particular medicine and provides information needed for its safe and effective use. It may show whether a patient is likely to benefit from a targeted therapy, face a greater risk of side effects, or require treatment monitoring. By connecting biological markers with treatment decisions, companion diagnostics support precision medicine, personalized medicine, and more informed cancer care.

What Is a Companion Diagnostic?

A companion diagnostic, often called a CDx, is a medical test that provides essential information about the use of a corresponding drug or biological treatment.

In simple terms, it helps answer an important question:

Is this treatment suitable for this patient?

The test may examine a gene mutation, gene amplification, protein-expression level, genomic signature, or another measurable characteristic associated with treatment response or safety.

A companion diagnostic may be used to identify patients who are likely to benefit from a medicine, exclude those who are unlikely to respond, recognize an increased risk of adverse effects, or monitor whether continued treatment remains appropriate. The test is connected to a defined therapy and intended use. A result validated for one medicine, disease, or sample type cannot automatically be applied to another.

Why Are Companion Diagnostics Important?

People with the same general diagnosis can have biologically different forms of disease. This is especially common in cancer, where molecular changes may determine how a tumor grows and which treatment is most likely to affect it. Traditional treatment decisions often rely on disease location, stage, symptoms, and pathology. Companion diagnostics add molecular information to this process.

They can help healthcare teams select therapies more accurately, avoid unnecessary exposure to treatments that are unlikely to work, and identify patients who may require additional safety consideration. For drug developers, these tests can also improve clinical-trial enrollment by selecting participants whose disease contains the biomarker targeted by an experimental medicine.

How Do Companion Diagnostics Work?

A companion diagnostic connects three elements:

1. A measurable biomarker
2. A validated diagnostic test
3. A corresponding treatment decision

For example, a therapy may be designed to inhibit a protein activated by a specific mutation. Before treatment begins, a diagnostic assay examines the patient’s sample for that alteration. If the required biomarker is detected, the patient may meet the molecular criteria for the treatment. If it is absent, another therapy may be considered. The final decision still depends on the complete clinical situation, including disease stage, previous treatment, general health, test quality, and the approved therapeutic indication.

Companion Diagnostic Versus Biomarker

A biomarker and a companion diagnostic are related, but they are not the same. A biomarker is the biological characteristic being measured. It may be a mutation, protein, gene-expression pattern, or molecular signature.

A companion diagnostic is the validated test used to detect or classify a biomarker for a specific treatment decision. A promising biomarker discovered during research does not immediately become a companion diagnostic. It must first be translated into a reliable assay and supported by analytical, clinical, and regulatory evidence.

Companion Versus Complementary Diagnostics

Companion and complementary diagnostics both provide treatment-related information, but their roles differ. A companion diagnostic provides information considered essential for the safe and effective use of a corresponding medicine. Testing is often required to determine treatment eligibility.

A complementary diagnostic offers useful information about the likelihood of benefit or risk, but its result is not necessarily required before the medicine can be used.

Benefits of Companion Diagnostics

The main benefits of companion diagnostics come from making treatment selection more precise.

More focused treatment selection

A CDx can identify the molecular feature targeted by a medicine. This helps match treatment with patients whose disease is more likely to respond.

Reduced unnecessary treatment

Patients without the required biomarker may avoid a therapy that is unlikely to provide sufficient benefit.

Improved safety

Some tests identify biological characteristics associated with serious treatment-related risks. This allows healthcare teams to consider safer alternatives or closer monitoring.

More efficient clinical trials

Biomarker-based enrollment can help drug developers study a treatment in the population most likely to respond.

Support for precision medicine

Companion diagnostics move care beyond a one-treatment-fits-all model by incorporating molecular information into medical decisions. These advantages create positive opportunities for more targeted research, efficient drug development, and increasingly informed patient care.

Companion Diagnostics in Precision and Personalized Medicine

Precision medicine uses information about genes, proteins, environment, lifestyle, and disease biology to guide prevention, diagnosis, and treatment. Personalized medicine is often used similarly, although precision medicine does not necessarily mean creating a unique treatment for every person. It commonly involves placing patients into biologically meaningful groups.

Companion diagnostics support this approach by identifying groups with a treatment-relevant biomarker. In cancer care, two patients may have tumors in the same organ but carry different molecular alterations. A diagnostic test can help show whether either tumor has the biological target required for a particular therapy.

Companion Diagnostics for Cancer Treatment

Oncology is the most established area for companion diagnostic testing. Many targeted therapies and some immunotherapies depend on measurable tumor characteristics. Frequently studied biomarkers include HER2, EGFR, BRAF, KRAS, BRCA1, BRCA2, PIK3CA, ALK, ROS1, RET, MET, NTRK, and PD-L1.

These markers can provide different types of information. A test may detect a mutation, measure protein expression, identify a gene fusion, reveal gene amplification, or evaluate a broader genomic signature. Examples of common testing relationships include HER2 analysis for selected HER2-targeted therapies, EGFR mutation testing for certain lung cancer treatments, and PD-L1 expression testing in particular immunotherapy settings. The exact test, medicine, disease indication, sample type, and cutoff must always be considered together. Tests that examine the same general biomarker may use different technologies or interpretation rules and may not be interchangeable.

Technologies Used in Companion Diagnostic Tests

Different technologies are selected according to the biomarker, sample, treatment, and intended clinical use.

Immunohistochemistry

Immunohistochemistry uses antibodies to detect proteins in tissue sections. It preserves information about where the protein is expressed and which cells contain it. IHC is commonly associated with protein biomarkers such as HER2 and PD-L1. Its performance can be influenced by tissue fixation, antibody selection, staining platform, scoring method, tumor heterogeneity, and cutoff values.

Fluorescence In Situ Hybridization

FISH uses fluorescent probes to detect selected genetic changes within cells. It can identify gene amplification, deletion, or rearrangement while preserving cellular context. Its main limitations include specialized interpretation and relatively limited multiplexing.

Polymerase Chain Reaction

PCR-based methods detect defined DNA or RNA targets. They can be fast, sensitive, and effective when the relevant alteration is already known. Real-time PCR, allele-specific PCR, and reverse-transcription PCR may be used depending on the biomarker. The main limitation is that focused assays examine fewer targets than broad sequencing approaches.

Digital PCR

Digital PCR divides a sample into many individual reactions, allowing sensitive detection and quantification of rare known variants. It can support focused mutation analysis, copy-number measurement, liquid-biopsy testing, and confirmation of selected results. However, it provides less molecular breadth than next-generation sequencing.

Next-Generation Sequencing

Next-generation sequencing can evaluate many genes and alteration types in one workflow. Depending on the assay, it may detect mutations, insertions, deletions, gene fusions, copy-number changes, and broader genomic signatures.

NGS is useful when tissue is limited or when several biomarkers must be assessed. Its challenges include complex validation, bioinformatics, variant interpretation, quality control, and higher data-processing requirements.

Liquid Biopsy

Some companion diagnostic tests examine circulating tumor DNA in plasma rather than relying only on tumor tissue. Liquid biopsy offers less invasive collection and may be useful when tissue is difficult to obtain. It can also capture molecular material released from more than one tumor location.

However, some tumors release very little DNA into circulation. A negative plasma result may therefore require cautious interpretation or follow-up tissue testing according to the approved test instructions.

How Is a Companion Diagnostic Developed?

Developing a companion diagnostic requires close coordination between researchers, diagnostic developers, pharmaceutical companies, clinical laboratories, and regulatory authorities.

Biomarker discovery

Researchers first identify a biological characteristic associated with treatment response, resistance, or toxicity. Discovery may involve genomics, proteomics, immunohistochemistry, sequencing, cell models, clinical samples, or functional assays.

Assay development

The biomarker is then converted into a practical test. Developers select the sample type, platform, targets, controls, cutoff, scoring system, and reporting rules.

Analytical validation

Analytical validation determines whether the test measures the biomarker reliably. It commonly examines accuracy, precision, analytical sensitivity, specificity, detection limits, reproducibility, sample stability, interference, cross-reactivity, and reagent consistency.

Clinical validation

Clinical validation determines whether the test correctly identifies the treatment-relevant patient population. The relationship between biomarker status and treatment outcome must be supported in the intended disease and population.

Regulatory review and deployment

The diagnostic and corresponding therapy are often developed in parallel. Once the required evidence is available, regulatory authorities evaluate the test for its defined intended use. After authorization, laboratories need suitable instruments, trained personnel, quality controls, reporting procedures, and reliable supplies.

Drug–Diagnostic Co-development

Drug–diagnostic co-development means planning the medicine and its associated test together. The biomarker strategy, assay design, clinical-trial enrollment, specimen collection, statistical plan, and regulatory pathway should be aligned early.

This approach helps ensure that the test used to select patients during clinical studies is suitable for future clinical use or can be appropriately connected to the final approved assay. Poor coordination may create delays if the medicine is ready for review, but the diagnostic has not generated enough evidence.

FDA-Approved Companion Diagnostic Tests

The FDA maintains an official list of cleared or approved companion diagnostic devices. This list includes tissue-based, plasma-based, molecular, protein-expression, and selected imaging tools linked to corresponding therapeutic products. A device should only be described as an FDA-approved companion diagnostic for the biomarker, treatment, disease, specimen, and intended use included in its authorization. Because new tests and treatment indications are added over time, official regulatory resources should be checked rather than relying on an old or static list.

What Makes a Reliable Companion Diagnostic?

A useful companion diagnostic must be scientifically relevant, analytically reliable, clinically validated, and practical enough to inform treatment. Important qualities include accurate biomarker detection, reproducible results, appropriate controls, clearly defined cutoffs, acceptable failure rates, suitable turnaround time, and consistent performance across qualified laboratories.

Sample quality is equally important. Tissue fixation, tumor-cell content, DNA or RNA degradation, decalcification, storage, and plasma-processing delays may all affect the result. A reliable test must therefore be validated for the exact specimen and application in which it will be used.

Challenges in Companion Diagnostic Development

One major challenge is tumor heterogeneity. Different parts of a tumor may contain different molecular features, so a small biopsy may not represent the entire disease. Limited tissue creates another difficulty, especially when several tests are required from one small specimen. Broad sequencing panels and liquid biopsy can help conserve material, but they introduce their own technical considerations.

Rare biomarkers can make validation difficult because relatively few positive samples may be available. Developers must also establish clinically meaningful cutoffs, manage assay failures, demonstrate cross-laboratory reproducibility, and adapt to changing treatment landscapes. Access, cost, reimbursement, laboratory capacity, and turnaround time can also affect whether an otherwise valuable test is available when a treatment decision must be made.

Research Tools Supporting CDx Development

Companion diagnostic development begins with biomarker and assay research. Recombinant proteins, antibodies, enzymes, molecular standards, cell models, and reference materials may support target validation, antibody screening, assay calibration, and prototype development.

Beta LifeScience provides recombinant proteins, antibodies, cytokines, enzymes, and custom protein services that may support biomarker discovery and early assay-development research. Research-use products should remain clearly distinguished from regulated clinical diagnostic devices unless they have completed the necessary clinical and regulatory development.

The Future of Companion Diagnostics

The field is moving from one-biomarker, one-drug testing toward broader and more flexible strategies. Future developments may include comprehensive genomic profiling, multi-analyte tests, plasma-based testing, digital pathology, improved protein-expression analysis, and more coordinated drug–diagnostic development.

Artificial intelligence may also support image analysis, variant interpretation, and complex biomarker classification. These systems will still require transparent validation and strong evidence before they can guide clinical decisions. The most valuable progress will come from tests that are not only technically advanced but also reliable, accessible, clinically meaningful, and connected to a clear treatment decision.

FAQs

What is a companion diagnostic in simple terms?

A companion diagnostic is a medical test linked to a specific treatment. It helps determine whether that treatment is suitable or safe for a particular patient.

Is a companion diagnostic required before treatment?

It is often required when the test provides information essential to the safe and effective use of the medicine. The requirement depends on the treatment labeling and intended use.

Is a biomarker the same as a companion diagnostic?

No. A biomarker is the biological characteristic being measured. A companion diagnostic is the validated test used to measure it for a defined treatment decision.

What technologies are used in companion diagnostics?

Common technologies include immunohistochemistry, FISH, PCR, digital PCR, next-generation sequencing, and liquid biopsy.

Conclusion

Companion diagnostics connect molecular testing with treatment selection. By identifying mutations, protein-expression patterns, gene amplifications, or other biomarkers, they help determine whether a medicine is suitable for a defined patient population.

Their role is central to precision medicine, personalized medicine, targeted therapy, and modern cancer care. However, a biomarker test becomes a true companion diagnostic only after the assay has been carefully developed, analytically validated, clinically supported, and authorized for a specific therapeutic use.